Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4174794 · 1 trial · 2 indications
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| Part A: LY4174794 | EXPERIMENTAL | Participants will receive LY4174794 administered subcutaneously (SC). |
| Part B: LY4174794 | EXPERIMENTAL | Participants will receive LY4174794 administered SC. |
| Part A & B: Placebo | PLACEBO_COMPARATOR | Participants will receive placebo administered SC. |
| Part C: LY4174794 | EXPERIMENTAL | Participants will receive LY4174794 administered intravenously (IV). |
| Name | Type | Description |
|---|---|---|
| LY4174794 | DRUG | Administered SC. |
| Placebo | DRUG | Administered SC. |
Inclusion Criteria: * Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease * Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m² * Have had a self-repo...
Top 20 of 32 competitors
LY4174794 is an investigational small molecule being developed for obesity. It is being studied in participants with obesity or overweight who are otherwise healthy. The drug is in Phase 1 clinical development and is not yet approved by regulatory authorities.
The molecular target of LY4174794 has not been disclosed. It is a small molecule being developed for the treatment of obesity, and its specific mechanism of action is not publicly available at this time.
LY4174794 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY.
LY4174794 is in Phase 1 clinical development. It is an investigational drug being studied for obesity and has not been approved by the FDA or any other regulatory agency.
LY4174794 is being studied in a Phase 1 clinical trial with the identifier NCT07654972. This trial is recruiting participants with obesity or overweight who are otherwise healthy, with an enrollment of 108 participants across the United States and Singapore.
No alternative names for LY4174794 have been disclosed. It is a unique investigational compound being developed by Eli Lilly and Company for the treatment of obesity.